2024
Multicenter Phase III Trial of Chemoradiation (CRT) with IMPT vs. IMRT for Oropharyngeal Squamous Cell Carcinoma (OPSCC): Secondary Analysis of Association of Lymphopenia with Treatment Modality, Emergency Room (ER) Visits and Hospital Admission (HA)
Grippin A, Foote R, Busse P, Rosenthal D, Hernandez M, Garden A, Sturgis E, Ferrarotto R, Gunn G, Patel S, Lee N, Lin A, Snider J, McDonald M, Henson C, Bajaj G, Kalman N, Parvathaneni U, Frank S. Multicenter Phase III Trial of Chemoradiation (CRT) with IMPT vs. IMRT for Oropharyngeal Squamous Cell Carcinoma (OPSCC): Secondary Analysis of Association of Lymphopenia with Treatment Modality, Emergency Room (ER) Visits and Hospital Admission (HA). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e755. DOI: 10.1016/j.ijrobp.2024.07.1658.Peer-Reviewed Original ResearchIntensity modulated proton therapyOropharyngeal squamous cell carcinomaAbsolute lymphocyte countAbsolute lymphocyte count nadirBaseline absolute lymphocyte countGrade 4 lymphopeniaMultivariate analysisTreatment modalitiesHospital admissionAdvanced stage oropharyngeal squamous cell carcinomaStage oropharyngeal squamous cell carcinomaMulticenter phase III trialPhase III randomized controlled trialsEmergency roomPhase III non-inferiority trialAssociation of lymphopeniaBilateral neck radiationBody mean doseStage III-IVAEffectiveness of treatment modalitiesSquamous cell carcinomaAssociated with increased ratesClinical implicationsER visitsSecondary analysisThe Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Wang L, Zhang Y, Ausat N, Hernandez M, Rosenthal D, Garden A, Ferrarotto R, Gunn G, Fuller C, Phan J, Morrison W, Lee A, Moreno A, Gross N, Spiotto M, Frank S. The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamous Cell Carcinoma (OPSCC). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s123-s124. DOI: 10.1016/j.ijrobp.2024.07.223.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaIntensity modulated proton therapyDNA scoreConcurrent chemoradiationTreatment failureNode dissectionInduction chemotherapyHuman papillomavirusHPV+ oropharyngeal squamous cell carcinomaHigh risk of treatment failurePhase III randomized trialRisk of treatment failureMulticenter phase III randomized trialPost-induction chemotherapyTreatment de-escalationHuman papillomavirus DNALymph node dissectionPhase III trialsSquamous cell carcinomaPotential of TFAJCC-7RT doseTumor controlTreatment toxicityPost-RTSurrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx
Gharzai L, Morris E, Nguyen-Tan P, Rosenthal D, Gillison M, Harari P, Garden A, Zanotti K, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e14. DOI: 10.1016/j.ijrobp.2024.01.035.Peer-Reviewed Original ResearchLocoregional progression-free survivalProgression-free survivalP16-positive oropharyngeal cancerOverall survivalOropharyngeal cancerIncreasing incidence of HPV-related cancersIncidence of HPV-related cancersP16-positive squamous cell carcinomaOptimal treatment paradigmMedian follow-upHPV-related cancersSquamous cell carcinomaMulticenter randomized trialClinical trial endpointsLocoregional progressionDistant metastasisLocal progressionCell carcinomaDefinitive treatmentTreatment paradigmDMFSFollow-upRandomized trialsIncreased incidenceTreatment effectsSurrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis
Gharzai L, Morris E, Suresh K, Nguyen-Tân P, Rosenthal D, Gillison M, Harari P, Garden A, Koyfman S, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Filion E, Dunlap N, Stokes W, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis. The Lancet Oncology 2024, 25: 366-375. PMID: 38423050, PMCID: PMC10962533, DOI: 10.1016/s1470-2045(24)00016-0.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalProgression-free survivalIntermediate clinical endpointsMetastasis-free survivalOverall survivalClinical endpointsOropharyngeal cancerComposite endpointIncidence of human papillomavirus (HPV)-related cancersP16-positive squamous cell carcinomaHuman papillomavirus (HPV)-related cancersP16-positive oropharyngeal cancerCancer treated with chemotherapyIndividual patient data meta-analysisMedian follow-upPatient data meta-analysisSquamous-cell carcinomaSquamous cell carcinomaPatient levelClinical trial endpointsTreatment effectsData meta-analysisLocoregional progressionNational Cancer InstituteDistant metastasis
2023
Patterns of failure for recurrent head and neck squamous cell carcinoma treated with salvage surgery and postoperative IMRT reirradiation
Mohamed A, Martin G, Ng S, Takiar V, Beadle B, Zafereo M, Garden A, Frank S, Fuller C, Gunn G, Morrison W, Rosenthal D, Reddy J, Moreno A, Lee A, Phan J. Patterns of failure for recurrent head and neck squamous cell carcinoma treated with salvage surgery and postoperative IMRT reirradiation. Clinical And Translational Radiation Oncology 2023, 44: 100700. PMID: 38058404, PMCID: PMC10695834, DOI: 10.1016/j.ctro.2023.100700.Peer-Reviewed Original ResearchLocoregional recurrenceSalvage surgeryRecurrent headNeck squamous cell cancerNeck squamous cell carcinomaPhysician's classificationMarginal failureSubsequent locoregional recurrenceSquamous cell cancerSquamous cell carcinomaPatterns of failureLogistic regression analysisDeformable image registrationAdjuvant reirradiationRadiological progressionSurgical salvageInitial recurrenceRecurrent diseaseSalvage rateRecurrent HNSCCCell cancerMucosal sitesCell carcinoma
2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Amit M, Nagarajan P, Rubin M, Yuan Y, Bell D, El-Naggar A, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Lu C, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Weber R, Wargo J, Basu S, Duan F, Yadav S, Sharma P, Allison J, Myers J, Gross N. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 2021, 27: 4557-4565. PMID: 34187851, PMCID: PMC8711237, DOI: 10.1158/1078-0432.ccr-21-0585.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaInflamed tumor microenvironmentSquamous cell carcinomaHead and neckCSCC-HNNeoadjuvant immunotherapyCell carcinomaTumor microenvironmentPathological responsePD-1 inhibitionCurative-intent surgeryPathological response rateBiomarkers of responseT cell clustersOS ratesNeoadjuvant treatmentPartial responseRecurrent diseaseExploratory endpointsPrimary endpointSecondary endpointsImmune biomarkersFollow-upCyTOF analysisPatients